Compare INBK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | ALXO |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.0M | 205.9M |
| IPO Year | 2013 | 2020 |
| Metric | INBK | ALXO |
|---|---|---|
| Price | $27.11 | $1.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $30.90 | $4.60 |
| AVG Volume (30 Days) | 37.0K | ★ 930.4K |
| Earning Date | 10-21-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $11,541,000.00 | N/A |
| Revenue This Year | $18.94 | N/A |
| Revenue Next Year | $14.34 | N/A |
| P/E Ratio | $47.40 | ★ N/A |
| Revenue Growth | ★ 101.84 | N/A |
| 52 Week Low | $17.05 | $1.05 |
| 52 Week High | $31.09 | $2.66 |
| Indicator | INBK | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 29.67 |
| Support Level | $25.04 | $1.37 |
| Resistance Level | $30.04 | $1.56 |
| Average True Range (ATR) | 0.89 | 0.10 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 40.87 | 12.32 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.